Raymond James & Associates’s 9 Meters Biopharma NMTR Stock Holding History

Raymond James & Associates’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,905	Closed	-$21K	–	4109
2022 Q3	$21K	Buy	4,905 +4,000	+442%	+$19.8K	﹤0.01%	3795
2022 Q2	$5K	Buy	905 +255	+39%	+$2.4K	﹤0.01%	3980
2022 Q1	$8K	Hold	650	–	–	﹤0.01%	4074
2021 Q4	$13K	Hold	650	–	–	﹤0.01%	4061
2021 Q3	$17K	Hold	650	–	–	﹤0.01%	4019
2021 Q2	$14K	Hold	650	–	–	﹤0.01%	4016
2021 Q1	$15K	Hold	650	–	–	﹤0.01%	3937
2020 Q4	$11K	Buy	650 +62	+11%	+$1.03K	﹤0.01%	3728
2020 Q3	$10K	Buy	+588	New	+$7.13K	﹤0.01%	3543
2018 Q4	–	Sell	-1,426	Closed	-$195K	–	3732
2018 Q3	$195K	Buy	+1,426	New	+$245K	﹤0.01%	3301

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Raymond James & Associates's NMTR Position: Q4 2022 in Review

Raymond James & Associates sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 4,905 shares — an estimated $21K sold.

Raymond James & Associates first reported a position in NMTR in Q3 2018 and held it in 10 quarters. The position peaked at $195K in Q3 2018. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

Raymond James & Associates reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
Raymond James & Associates sold 4,905 9 Meters Biopharma shares in Q4 2022, an estimated $21K.
Raymond James & Associates first reported a position in 9 Meters Biopharma in Q3 2018 and held it in 10 quarters.
Raymond James & Associates's 9 Meters Biopharma position peaked at $195K in Q3 2018.
42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.